1McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects [J]. Blood, 2001, 97(11): 3390-3400.
2Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic lcukaemia[J]. Br J Haematol, 1995, 91(2) : 341.
3Locattelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease[J].Blood, 2003, 101(6): 2137-2143.
4Bruno B, Sorasio R, Patriarca F, et al. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma[ J]. Eur JHaematol, 2007, 78(4) : 330 - 337.
5Grigg A, Bardy P, Byron K, et al. Fludarabine-base non-myeloblative chemotherapy follow-ed by infusion of HLA-identical stem cells for relapsed[J]. Leuk Lymphoma, 1999, 23(2) : 107 - 112.
6Srinivasan R, Takahashi Y, Mccoy JP, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-basedhaematopoietic cell transplantation[J]. Br J Haematol, 2006, 133(3) : 305 -314.
7Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine[ J]. Ann Intern Med, 1998, 129(7) : 559 -566.
8Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-ceIIand plasma cell apoptosis by multiple pathways [J]. Transplantation, 2005, 79(11): 1507- 1515.
9Brennan DC. Faith supported by reason: Mechanistic support for the use of polyclonal anti-bodies in transplantation [ J ]. Transplantation, 2003, 75(5) : 577 -578.
10Kaplan JM, Woodworth L, Smith K, et al. Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-β1 in the MRL/lpr lupus mouse model[ J]. Lupus, 2008, 17 (9) : 822 - 831.
5John B,Richard C.Non-myeloablative stem cell transplants.British Journal of Haematology.2000;111(1):6-17.
6Hermann S,Klein SA,Jacobi V,et al.Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens.British Journal of Haematology.2001;113(2):446-454.
7Hashmi S,Becker M.Is consolidation chemotherapy necessary before non-myeloablative transplantation in AML?.Leuk Res.2011;35(7):841-843.
8Pollack SM,O'Connor TP,Hashash J,et al.Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation:A Clinical Review.American Journal of Clinical Oncology.2009;32(6):618-628.
9Alyea EP,Kim HT,Ho V,et al.Comparative outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than50years of age.Blood.2005;105(4):1810-1814.
10Michele F,Alessandro B,Ileana B,et al.Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies:Results from the GITMO(Gruppo Italiano Trapianto Midollo Osseo)multicenter prospective clinical trial.American Journal of Hematology.2007;82(10):863-866.
